December 2011. Volume 7. Number 4

A new vaccine against tuberculosis: Safe and effective?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis. 2011;203:1832-43.
Reviewers: Orejón de Luna G1, de Lucas García N2.
1CS General Ricardos. Madrid. España.
2Hospital de Tomelloso. Tomelloso. Ciudad Real. España.
Correspondence: Gloria Orejón de Luna. Email: gloriaglo04@gmail.com
Reception date: 02/10/2011
Acceptance date: 03/10/2011
Publication date: 05/10/2011

Abstract

Authors' conclusions: the new vaccine against tuberculosis, MVA85A, was safe and produced a high and durable T cell response in infants.

Reviewers' commentary: the study has methodological limitations that call into question the authors' conclusions. However it opens the door to developing a new vaccine against tuberculosis in children, requiring more studies to assess its immunogenicity, safety and effectiveness.

How to cite this article

Orejón de Luna G, de Lucas García N. Una nueva vacuna frente a la tuberculosis: ¿segura y eficaz? Evid Pediatr. 2011;7:85.

AVC | Critically appraised articles

Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis. 2011;203:1832-43.
Reviewers: Orejón de Luna G1, de Lucas García N2.
1CS General Ricardos. Madrid. España.
2Hospital de Tomelloso. Tomelloso. Ciudad Real. España.
Correspondence: Gloria Orejón de Luna. Email: gloriaglo04@gmail.com
Reception date: 02/10/2011
Acceptance date: 03/10/2011
Publication date: 05/10/2011

How to cite this article

Orejón de Luna G, de Lucas García N. Una nueva vacuna frente a la tuberculosis: ¿segura y eficaz? Evid Pediatr. 2011;7:85.

References

  1. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(1)- and CD4(1)-T-cell epitopes from antigen 85A. Infect Immun. 2002;70:1623-6.
  2. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008;198:544-52.
  3. Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, Donkor SA et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One. 2008;3:e2921.
  4. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2010;40:279-90.
  5. Dockrell HM. Another step down the development pipeline for the novel tuberculosis vaccine MVA-85A. J Infect Dis. 2011;203:1708-9.
05/10/2011

Linked Comment